登录

Well-healthcare Raises ¥100 Million in Extended Series A Round

Mailman 2021-08-10 15:57

汇健科技
http://www.well-healthcare.com/
企业数据由 动脉橙 提供支持
肿瘤液体活检产品开发商 | 战略融资 | 运营中
中国-浙江
2022-04-07
悬壶汇智
查看

(VCBeat) July. 29, 2021 -- In June 2021, Well-healthcare Technologies Co., Ltd. ("Well-healthcare") extended the Series A investment round by an additional ¥100 million. This round of financing was jointly led by Longmen Capital and Tianhui Capital, with participation from Lotus Lake Ventures and Jiyang Talent Fund, and the existing investor Thunderstorm Venture Capital. WinX Capital acted as the exclusive financial advisor.


After completion of this round of financing, Well-healthcare will further develop the multiple-omics accurate diagnosis platform based on "3T", promote real-world clinical researches and the development of precise diagnosis products based on multiple omics, meet the demand of clinical application in different scenarios, build the high-throughput mass spectrometry industry chain, and accelerate the industrialization and marketization of main businesses and products.


Well-healthcare's 3T-based multi-omics precision diagnosis platform consists of an innovative diagnostic methodology system based on MT (Materials Technology), BT (Biotechnology) and IT (Information Technology). It has successfully developed a high-throughput mass spectrometry platform and an artificial olfactory system platform at the international forefront level, and built a product development and application system that is suitable for various types of sample, multi-omics tests and diversified clinical scenarios.


Well-healthcare has cooperated with leaders in the industry to develop the world's first sets of peptides identification in tumors, the ClinMS-Plat®Ⅰ mass spectrometry diagnostics system, which is going to be launched. Besides, Well-healthcare built the first diagnostic reagent and AI-based liquid biopsy diagnosis model for colorectal cancers, which is called Bio-pSi®, with an accuracy over 90%.


>>>>

About Longmen Capital


Founded in 2017, Longman Capital focuses on investments in companies engaged in innovative medicine and life science technology in early and early-growth stages. The core team has a wealth of operation and investment experience in the pharmaceutical field. At present, it has initiated and established the third-phase fund, with a management scale of 2 billion yuan.


>>>>

About Lotus Lake Ventures


Founded in 2001, Lotus Lake Ventures is an investment firm committed to investing in science and technology innovation enterprises, focusing on high-tech enterprises with core competitiveness in the initial stage and growth stage in the fields of information technology, life science and clean technology, etc.

相关赛道 IVD
注:文中如果涉及企业数据,均由受访者向分析师提供并确认。
声明:动脉网所刊载内容之知识产权为动脉网及相关权利人专属所有或持有。转载请联系tg@vcbeat.net。
推荐阅读

拿骚浸信会医疗中心任命主席

Becker's Hospital Review 2024-07-23 04:50

ECU健康医院院长退休

Becker's Hospital Review 2024-07-23 04:40

TransCode Therapeutics,股份有限公司宣布拟公开发行普通股

GlobeNewswire 2024-07-23 04:07

Mailman

共发表文章3245篇

最近内容
查看更多
  • 知之甚少:调研885名投资人后,原来美国VC们这样做决策

    2023-03-20

  • 辉瑞想要收购Seagen只是开始,这才是2023年并购的两大趋势

    2023-03-05

  • 【融资】核药企业Ratio再融资2000万美元,和拜耳合作研究新前列腺癌放射性疗法

    2023-02-09

相关公司
查看更多

暨阳人才基金

创业投资机构

立即沟通

荷塘创投

科技创新领域投资机构

立即沟通

汇健科技

肿瘤液体活检产品开发商

立即沟通
产业链接
查看更多